Bonnie H. Anderson is the President and Chief Executive Officer of Veracyte, a molecular diagnostics company that is pioneering the field of molecular cytology. Her career spans nearly 30 years in regulated diagnostics and life science markets. Under Ms. Anderson's leadership, the company has achieved significant commercialization milestones since its formation as Veracyte in 2008. These include the launch of its first product - the Afirma® Thyroid FNA Analysis - designed to help reduce unnecessary surgeries in thyroid nodule assessment; national coverage decisions for its gene expression test; a global co-promotion partnership with Genzyme, a Sanofi company; and publication of strong clinical validation study results in the New England Journal of Medicine. In 2011, Veracyte was named to The Wall Street Journal's "The Next Big Thing" list of the top 50 venture-backed companies and in 2013, the company was honored with FierceMedicalDevice's "Fierce 15" award.
Prior to Veracyte, Ms. Anderson provided strategic consulting services to venture capital firms and early-stage businesses following 18 years in leadership positions at Beckman Coulter. As Vice President of the company's intrapreneurial start-up Immunomics Operations, she successfully positioned its novel MHC tetramer technology as a vehicle for drug and vaccine developers to monitor ex-vivo immune response.
Ms. Anderson graduated from Indiana University of Pennsylvania with a Bachelors of Science degree in Medical Technology and in 2012 was honored as a "Distinguished Alumni" award recipient. In 2013, she received the Silicon Valley Business Journal's "Women of Influence" award, and was named one of the "Most Influential Women in Bay Area Business" and one of the "Best Bay Area Life Sciences CEOs" by the San Francisco Business Times.